A critical appraisal of the quality of the trials is needed. Bempedoic acid did not have an effect on secondary prevention. This was not discussed in the NEJM article. Data sharing needs to be done or the results should not be published. Also BMJ article regarding Repatha demonstrated that the CRF didn’t match the results. Data sharing is required.

Thank you very much indeed for such an informative lecture. I started taking Mavacamten, here in the United Kingdom, only two weeks ago (we are behind the US in distributing this First in Class medication). So it is early days but I remain cautiously optimistic. Whilst I have tried to keep up with the trial data for these CMI medications, I found your discussion of the clinical management very helpful. The possibility of long-term remodelling remains tantalising, but for now I need to be cautiously optimistic about receiving improvements in my symptoms and NYHA status over the coming months.

Nice!

Nice presentation. Thank you

👌👌👌

CAC is a late manifestation of atherosclerosis. We don’t have to wait for CAC > 0 to treat the patient. The most spartan of diets associated with exercise would reduce LDL and Apo B to what level? 10%? 7%? It is impossible not to use drugs to reduce cholesterol and MACE.

Atherosclerosis is not a inexorable condition . Is there a level of ApoB that that if maintained throughout life would not let plaques to build up ? ApoB less than 55 mg/dl for instance .

Excellent presentation🐸❤️thank you